Business Wire

Boyd Corporation Continues Global Material Science Expansion with Grando Acquisition

1.12.2021 10:00:00 EET | Business Wire | Press release

Share

Boyd Corporation, a world-leading innovator of technologies in engineered materials and thermal management, today announced the acquisition of Grando, a Belgium-based specialist in rubber, foam, and plastic polymer science for the highly-regulated rail and industrial technology industries. The acquisition deepens and diversifies Boyd’s global material science portfolio, broadens Boyd’s regional polymer manufacturing in Europe, and further expands its footprint into Belgium with increased market penetration in France, Italy, Spain, and Belgium.

“Grando’s polymer scientists and converting technologists expand Boyd’s elastomer innovation capability while adding capacity and regional service for our European customers,” stated Boyd CEO Doug Britt. “We’re accelerating our innovation in high growth markets like eMobility, renewable energy, battery storage, and industrial technology. Additional expertise and capability from Grando will further accelerate this innovation while expanding regionally.”

Boyd’s value-driven innovation and technology creates marketable differentiation for its customers. Grando bolsters Boyd’s custom engineered material manufacturing which is optimized to balance high performance, sustainability, and lean manufacturing. Boyd’s robust global manufacturing footprint, design expertise, and rapid prototyping helps customers accelerate time to market, ensure business continuity, and efficiently manage global supply chain needs.

“Grando’s commitment to high quality products, excellent customer service, superior technical support, and unrelenting reliability in delivery align to Boyd’s values. We’re accelerating growth in Europe and Grando’s manufacturing operations in Belgium, talented staff, and valued customers magnify this acceleration,” said Boyd European Managing Director Joop Ruijgrok.

About Boyd Corporation

Boyd Corporation is a world-leading innovator of technologies in material science, engineered materials, and thermal management that seal, protect, interface with, and cool our customers’ most critical applications. ​We embrace science to solve ambitious performance targets. Boyd architects material innovation, combining technologies in novel ways to redefine the possible. We gain unparalleled technology insight solving complex challenges across the leading industries we serve.​ Our solutions maximize performance in 5G infrastructure and the world’s most advanced data centers; enhance reliability and extend range for electric and autonomous vehicles; advance the accuracy of cutting-edge personal healthcare and diagnostic systems, enable performance critical aircraft and defense technologies; and accelerate innovation in next-generation electronics and human-machine-interface. Core to Boyd’s global, large-scale manufacturing is a deep commitment to protect the environment with sustainable, lean operations that reduce waste and minimize carbon footprint.​

Visit us at www.boydcorp.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Amie Jeffries
Boyd Corporation
amie.jeffries@boydcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release

FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu

Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release

Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye